ASMBS Position Statement on the Impact of Metabolic and Bariatric Surgery on Nonalcoholic Steatohepatitis

Guilherme S. Mazzini, Toms Augustin, Sabrena Noria, Carlos Romero-Marrero, Na Li, Bilal Hameed, Dan Eisenberg, Dan E. Azagury, Sayeed Ikramuddin

Research output: Contribution to journalArticlepeer-review

8 Scopus citations
Original languageEnglish (US)
Pages (from-to)314-325
Number of pages12
JournalSurgery for Obesity and Related Diseases
Volume18
Issue number3
DOIs
StatePublished - Mar 2022

Bibliographical note

Funding Information:
B. Hameed reports grant support from Gilead, Intercept, Genfit, Pliant Therapeutics, Novo Nordisk, and Cyma Bay; serving on the advisory board for Mallinckrodt and Pleiogenix; serving as a consultant for Gilead and Pioneering Medicine VII, Inc; stock held by spouse from Intercept Pharmaceuticals; and stock held by self from Pleiogenix. D.E. Azagury reports being a consultant for and owning stock from Form Health and GI windows; stock and scientific advisory board membership for Endolumik; and being a consultant for Verily. S. Ikramuddin reports being on the advisory board for Novo Nordisk and receiving grant support from ReShape Life Sciences and NIH. All other authors have nothing to disclose.

Funding Information:
Sayeed Ikramuddin is funded by NIH grants 1R01DK12832501 and 5R21DK12283202.

Keywords

  • Bariatric Surgery
  • Humans
  • Non-alcoholic Fatty Liver Disease/etiology
  • Obesity, Morbid/complications

PubMed: MeSH publication types

  • Journal Article

Cite this